Astellas Pharma Inc 2011 AR2
The report outlines Astellas Pharma Inc.'s financial and operational performance for the fiscal year ended March 31, 2011, highlighting its progress toward becoming a Global Category Leader. Key achievements include the strategic acquisition of OSI Pharmaceuticals, Inc., which significantly expanded the company's oncology pipeline, and the regulatory filing of overactive bladder treatment mirabegron in Japan, the US, and Europe. Despite facing intense generic competition for mainstay products Prograf and Harnal in the US, the company expanded its global sales network across four key regions. Additionally, the report details Astellas' corporate social responsibility initiatives, focusing on work-life balance, biodiversity preservation, and community volunteer activities through its 'Changing Tomorrow Day' program.
Company: Astellas Pharma Inc
Sector: Manufacturing
Country: Japan
Year: 2011
Type: AR2
Pages: 88
Back to company
Astellas Pharma Inc
Annual Report
The report outlines Astellas Pharma Inc.'s financial and operational performance for the fiscal year ended March 31, 2011, highlighting its progress toward becoming a Global Category Leader. Key achievements include the strategic acquisition of OSI Pharmaceuticals, Inc., which significantly expanded the company's oncology pipeline, and the regulatory filing of overactive bladder treatment mirabegron in Japan, the US, and Europe. Despite facing intense generic competition for mainstay products Prograf and Harnal in the US, the company expanded its global sales network across four key regions. Additionally, the report details Astellas' corporate social responsibility initiatives, focusing on work-life balance, biodiversity preservation, and community volunteer activities through its 'Changing Tomorrow Day' program.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2011
Reporting Period
Apr 1, 2010 - Mar 31, 2011
Fiscal Year
2011
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees